Premium
Pharmacological interaction of α‐bisabolol and diclofenac on nociception, inflammation, and gastric integrity in rats
Author(s) -
Ortiz Mario I.,
CariñoCortés Raquel,
PonceMonter Héctor A.,
CastañedaHernández Gilberto,
ChávezPiña Aracely Evangelina
Publication year - 2018
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21418
Subject(s) - diclofenac , nociception , pharmacology , analgesic , carrageenan , inflammation , medicine , chemistry , receptor
Preclinical Research & DevelopmentThe combination of nonsteroidal anti‐inflammatory drugs (NSAIDs) with herbal products having analgesic and anti‐inflammatory effects may increase their beneficial effects and limit their side effects. In this study, the effects of an interaction between α‐bisabolol and the NSAID, diclofenac on nociception (formalin test), inflammation (paw inflammation produced by carrageenan) and gastric injury in rat was assessed. Diclofenac, α‐bisabolol, or diclofenac–α‐bisabolol combinations produced antinociceptive and anti‐inflammatory effects in rat ( p < .05). The systemic administration of diclofenac, but not α‐bisabolol, produced gastric damage while the diclofenac–α‐bisabolol combinations produced limited gastric damage. Effective dose (ED 40 ) values were determined for each individual drug and analyzed isobolographically. The theoretical ED 40 values for the antinociceptive (98.89 mg/kg) and the anti‐inflammatory (41.2 mg/kg) effects differed from the experimental ED 40 values (antinociception: 38.7 mg/kg and anti‐inflammation: 13.4 mg/kg). We concluded that the interactions between diclofenac and α‐bisabolol are synergistic. These data suggest that the diclofenac–α‐bisabolol combinations can interact to produce minor gastric damage, thereby offering a safer therapeutic alternative for the clinical management of inflammation and/or inflammatory pain.